Embryonic Stem Cell Research Expands With U.S. Funds (Update1)

 Stem cell research in the U.S. will expand under rules that allow federal government funding for scientists working with unused embryos created at fertility clinics, freeing hundreds of cell lines for study.

The final guidelines released today by the National Institutes of Health increase the number of stem cell lines available for research from the current 20, the acting director of the agency, Raynard Kington, said today in a conference call with reporters. The rules ban U.S. funding to scientists using stem cells from embryos created solely for research purposes. Global Stem Cell and Regenerative Medicine Index. Most of the stocks in the index got a major boost  from the widely anticipated executive order from President Obama to eliminate the restrictions on federal funding of stem cell research enacted in 2001 under President George W. Bush.

The move allows federally funded researchers to use hundreds of new embryonic stem cell lines for what remains long-term but very promising research which has the potential to cure a wide variety of conditions, including diabetes, paralysis, Parkinson's disease, and many others.

On a year-to-date basis (YTD), the stem cell index is up 39% on an equal-weight basis, thanks to major gains in many of the smallest companies in the index with the companies listed in the table in descending order by their YTD stock price changes. The stem cell index performance compares favorably to losses of 17.6% for the Healthcare Sector SPDR (XLV), 16.9% for iShares Nasdaq Biotech (IBB),Funding for new stem cell lines require documents showing the cells were donated, and stem cells already involved in research and those from other countries can be approved by a working group at the NIH, a U.S. research agency. An earlier draft of the guidelines released for public The new guidelines are “a big step forward,” said Susan Solomon, chief executive officer of the New York Stem Cell Foundation, in a telephone interview today. The absence of a working group option “may well have been an oversight in the draft version.”

Approved stem cell lines will be listed on a registry that research institutions can use for grant proposals, according to the agency’s Web site. The rules take effect tomorrow.



More articles Cell Therapeutics, Inc

More articles Stem Cell Companies

More articles Stem Cell Stocks

More articles BioMimetic Therapeutics (BMTI)

More articles Pluristem Therapeutics-PTSI

More articles Osiris Therapeutics-OSIR

More articles Cytori Therapeutics, Inc.

More articles ThermoGenesis (KOOL)

More articles Nutra Pharma (OTCBB:NPHC)

More articles Human Embryonic Stem Cell Market

More articles RTI Biologics (RTIX)

More articles Aastrom Biosciences -ASTM



XOMA 052 Designated Orphan Drug by FDA ...
Published:Wed, 04 Aug 2010 05:00:00 -0700
BERKELEY, Calif. -- XOMA Ltd. , a leader in the discovery and development of therapeutic antibodies, announced that the U.S. Food and Drug Administration has designated XOMA 052, ......
XOMA to Announce 2010 Second Quarter Fi...
Published:Mon, 02 Aug 2010 05:00:00 -0700
BERKELEY, Calif. -- XOMA Ltd. , a leader in the discovery and development of antibody therapeutics, announced that the company will host a webcast conference call on Monday, Augus......
XOMA 052 Orphan Drug Designation for Be...
Published:Thu, 29 Jul 2010 05:00:00 -0700
BERKELEY, Calif. -- XOMA Ltd. , a leader in the discovery and development of therapeutic antibodies, announced that the Committee for Orphan Medical Products of the European Medic......
Biotech Stocks: Depomed, Dendreon lead ...
Published:Wed, 04 Aug 2010 07:55:59 -0700
Depomed lead gains among drug stocks a day after it said Pfizer will not file a patent infringement lawsuit to prevent the launch of a painkiller.......
Trader Favorite Dendreon Spikes On Prov...
Published:Wed, 04 Aug 2010 08:00:00 -0700
After soaring higher on the FDA approval of its Provenge prostate cancer vaccine in April, volatile Dendreon quickly retreated to well below its pre-approval pricing, but sales fi......
© 2010 | Privacy Policy | Powered By Noomle.com | SiteMap